🇺🇸 FDA
Patent

US 11498963

Anti-LILRB antibodies and their use in detecting and treating cancer

granted A61KA61K2039/505A61K39/3955

Quick answer

US patent 11498963 (Anti-LILRB antibodies and their use in detecting and treating cancer) held by The Board of Regents of the University of Texas System expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2039/505, A61K39/3955, A61K45/06, A61P